In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on IntelliPharmaCeutics International (NASDAQ: IPCI), with a price target of $2.50. The company’s shares closed on Friday at $0.42, close to its 52-week low of $0.32.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -2.8% and a 39.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Synergy Pharmaceuticals Inc.
IntelliPharmaCeutics International has an analyst consensus of Moderate Buy, with a price target consensus of $2.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.92 and a one-year low of $0.32. Currently, IntelliPharmaCeutics International has an average volume of 259.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.
